Emicizumab was first approved by the Food and Drug Administration in 2017 to treat hemophilia A in patients with FVIII inhibitors. As patients without FVIII inhibitors also start taking this medication, clinical and laboratory experts provide insights about the most appropriate diagnostic testing for monitoring and managing patients taking this…